8-K: P3 Health Partners Targets Profitability in 2026

P3 Health Partners announced Q4 and full-year 2025 results, projecting a significant Adjusted EBITDA improvement and a path to profitability in 2026.

Summary

• Full-year 2025 total revenue was $1.46 billion, a decrease from $1.50 billion in 2024.
• Full-year 2025 net loss was $323.1 million, compared to a net loss of $310.4 million in 2024.
• Full-year 2025 Adjusted EBITDA loss was $161.3 million, an improvement from $167.2 million in 2024.
• Normalized Adjusted EBITDA loss for 2025 was $149.1 million, a $43.9 million improvement from $193.0 million in 2024.
• At-risk membership for full-year 2025 was approximately 116,000, an 8% decrease from 126,000 in 2024, attributed to intentional network alignment.
• Capitated revenue PMPM improved 5% year-over-year to $1,026 for the full year 2025.
• The company projects 2026 Adjusted EBITDA to be in the range of negative $20 million to positive $40 million, with a midpoint of $10 million, representing approximately $170 million in year-over-year improvement.
• 2026 guidance also includes total revenues between $1.5 billion and $1.7 billion, and at-risk members between 107,000 and 117,000.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While the 2026 guidance projects a significant turnaround towards profitability, the 2025 financial results show worsening net losses, declining cash, and a negative equity position, indicating substantial financial challenges that temper the optimism for the future.

Positives

• Normalized Adjusted EBITDA loss improved by $43.9 million year-over-year in 2025, reaching $149.1 million compared to $193.0 million in 2024.
• Capitated revenue PMPM improved by 9% year-over-year to $1,060 in Q4 2025 and 5% year-over-year to $1,026 for the full year 2025.
• Management projects a significant year-over-year Adjusted EBITDA improvement of approximately $170 million in 2026, targeting a midpoint of $10 million (ranging from negative $20 million to positive $40 million).
• Net cash used in operating activities improved in 2025 to $(91,238)k from $(110,128)k in 2024.

Negatives

• Net loss increased to $323.1 million in 2025 from $310.4 million in 2024.
• Fourth quarter 2025 medical margin was negative $28.7 million (negative $83 PMPM), a significant decline from $7.3 million ($19 PMPM) in the prior year quarter.
• At-risk membership decreased by approximately 8% year-over-year to 116,000 for full-year 2025, and is projected to further decrease in 2026 to a range of 107,000 to 117,000.
• Cash and restricted cash decreased from $44,102k at the end of 2024 to $25,807k at the end of 2025.
• Total Stockholders (Deficit) Equity significantly declined from $75,936k in 2024 to $(155,232)k in 2025, indicating a negative equity position.
• Long-term debt, net, more than doubled from $108,907k in 2024 to $228,374k in 2025.

Risks

• Ability to continue as a going concern.
• Potential need to raise additional capital to fund existing operations or develop and commercialize new services or expand operations.
• Ability to achieve or maintain profitability.
• Ability to maintain compliance with debt covenants in the future, or obtain required waivers from lenders if future operating performance falls below current projections.
• Risk of recognizing non-cash charges to operating earnings for goodwill and/or other intangible asset impairment if there are material changes to management's assumptions.
• Ability to identify and develop successful new geographies, physician partners, payors, and patients.
• Changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to services.
• Ability to fund growth and expand operations.
• Changes in laws and regulations applicable to the business.
• Ability to maintain relationships with health plans and other key payors.
• Impact of fluctuations in risk adjustments.
• Ability to establish and maintain effective internal controls.
• Ability to maintain compliance with California regulations related to financial solvency and operational performance.
• Ability to maintain the listing of securities on Nasdaq.
• Increased labor costs and medical expense.
• Ability to recruit and retain qualified team members and independent physicians.

Future Outlook

P3 Health Partners projects 2026 Adjusted EBITDA to be between negative $20 million and positive $40 million, with a midpoint of $10 million, representing approximately $170 million in year-over-year improvement. The company anticipates total revenues for 2026 to be in the range of $1.5 billion to $1.7 billion and at-risk members between 107,000 and 117,000. Management believes these efforts position the company for a clear path to profitability and strengthened long-term earnings power, partly through smart growth in new Medicare Advantage geographies with a deliberate glidepath toward full risk.

Management Comments

• "2025 was a year of meaningful progress in repositioning the business. We strengthened our contract economics, improved provider alignment, and built a more disciplined operating foundation."
• "With that work in place, we enter 2026 with a clear path to profitability and approximately $170 million of expected year-over-year EBITDA improvement at the midpoint of our guidance range."
• "Additionally, our new Medicare Advantage geography reflects our approach to smart growth with a deliberate glidepath toward full risk that we believe will strengthen the long-term earnings power of the platform."

Industry Context

StockSavvy.ai notes that P3 Health Partners' focus on 'intentional network alignment' and 'smart growth' in new Medicare Advantage geographies aligns with a broader industry trend towards value-based care models and optimizing patient populations for better financial outcomes. The emphasis on improving contract economics and provider alignment is crucial in a competitive and margin-pressured healthcare services sector, where efficient population health management is key to profitability.

Comparison to Industry Standards

• StockSavvy.ai observes that P3 Health Partners' reported net loss of $323.1 million in 2025, while an increase from 2024, is not uncommon for growth-oriented healthcare companies investing in value-based care infrastructure. However, the negative stockholders' equity of $(155.2) million raises concerns about financial stability compared to more established, profitable peers like Humana or UnitedHealth Group, which consistently report strong positive equity and net income.
• The projected $170 million year-over-year Adjusted EBITDA improvement to a positive midpoint of $10 million in 2026, if achieved, would represent a significant turnaround. This trajectory is ambitious but necessary to catch up with industry leaders who have already achieved substantial positive EBITDA margins in their value-based care segments.
• The decrease in at-risk membership by 8% in 2025, attributed to "intentional network alignment," suggests a strategic shift towards higher-quality or more profitable members, a tactic also employed by companies like Oak Street Health (now part of CVS Health) to optimize their patient panels, even if it means short-term membership declines.
• The improvement in capitated revenue PMPM to $1,026 in 2025 indicates better per-member economics, which is a positive sign in line with industry efforts to maximize revenue from each patient under capitation models, similar to strategies seen in successful Medicare Advantage providers.

Related Party Transactions

• The consolidated balance sheets include net amounts due to affiliates totaling $46.8 million as of December 31, 2025, and $40.3 million as of December 31, 2024, which are eliminated in consolidation.

Stakeholder Impact

• Shareholders: Potential for significant share price volatility due to current losses and negative equity, but also potential upside if 2026 profitability guidance is met. The explicit mention of "ability to continue as a going concern" and "potential need to raise additional capital" are significant concerns.
• Employees: The mention of "severance expense in connection with reorganization of workforce" for 2025 and "severance and related expense in connection with our chief executive officer transition" for 2024 suggests past workforce adjustments, which could impact employee morale and stability.
• Health Plans/Payors: The company's ability to maintain relationships with health plans and other key payors is crucial for its capitated revenue model.
• Providers: Improved provider alignment is a stated goal, suggesting efforts to strengthen relationships with affiliated primary care providers.
• Creditors: Increased long-term debt and the mention of "ability to maintain compliance with our debt covenants" indicate heightened scrutiny from creditors.

Next Steps

• Host a conference call and webcast on March 26, 2026, at 4:30 PM ET to discuss the results.
• Continue efforts to strengthen contract economics, improve provider alignment, and build a disciplined operating foundation.
• Execute on smart growth strategy in new Medicare Advantage geographies with a glidepath toward full risk.
• Work towards achieving the 2026 Adjusted EBITDA guidance midpoint of $10 million.

Key Dates

Recommendation

While P3 Health Partners reported substantial net losses and a negative equity position for 2025, raising significant concerns about financial health and going concern risk, the aggressive 2026 guidance projecting a $170 million Adjusted EBITDA improvement to a positive midpoint of $10 million suggests a potential turnaround. The 'intentional network alignment' and improved capitated revenue PMPM are positive operational signs. However, the company's high debt and explicit mention of potential capital raise needs introduce considerable uncertainty. A 'hold' recommendation is appropriate for investors who can tolerate high risk and are willing to wait to see if management can execute on its ambitious 2026 profitability targets, while acknowledging the severe financial challenges.

Keywords

P3 Health Partners, PIII, Financial Results, Earnings, 2025, 2026 Guidance, Adjusted EBITDA, Net Loss, Medical Margin, At-risk Membership, Population Health Management, Medicare Advantage, Value-Based Care, Healthcare, SEC Filing